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Background: To effectively assess and correct for inter-
method variability, calibration and control materials
(CCMs) must show the same intermethod behavior as
patient sera, i.e., they must be commutable. We describe
the commutability of selected CCMs for lipase assays,
the impact of noncommutability of CCMs in normaliz-
ing patient results, and characteristics of reagents that
affect assay specificity and commutability.
Methods: Lipase was measured in 98 patient sera and in
29 commercial CCMs, with 2 commercial methods using
different substrates and with 4 experimental methods
using 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6-meth-
ylresorufin) ester as substrate and colipase as cofactor,
but differing in the stabilizing proteins used and in the
size of the substrate micelles.
Results: The noncommutability rate, i.e., the frequency
of aberrant intermethod behavior of CCMs in compari-
son with patient sera, was 27% for liquid CCMs and 47%
for lyophilized CCMs. The normalized residuals, mea-
suring the degree of noncommutability, were2.3 to 2.4
for CCMs with “normal” lipase activity, and3.5 to 21.7
for CCMs with higher lipase activity. Recalculation of
patient results with CCMs as calibrators decreased or
increased the original bias according to whether the
CCMs were commutable.
Conclusions: For the lipase methods in this study, the
frequency of noncommutability of CCMs is affected by
assay-specific characteristics, including size of substrate
micelles and the presence or absence of added proteins.
© 2001 American Association for Clinical Chemistry
The measurement of serum lipase (triacylglycerol acylhy-
drolase; EC 3.1.1.3) activity is a well-established diagnos-
tic test for acute pancreatitis (1, 2). Large discrepancies
among different methods have been described (1, 3-5),
possibly leading to incorrect interpretation of test results,
notwithstanding the moderately high biologic variation of
serum lipase (intraindividual, 23%; interindividual, 33%)
(6 ). Discrepancies among the results of different methods
may reflect, in part, the lack of a reference method for the
titration of calibrators and the use of calibrators exhibiting
differences in catalytic properties (7 ).
In the standardization process, the intermethod behav-
ior of calibration and control materials (CCMs)4 must be
the same as that of fresh patient sera to effectively
measure intermethod variability and to equalize catalytic
activity measurements. The ability of CCMs to show
intermethod behavior comparable to that observed when
measuring the same quantity in patient sera is referred to
as “commutability” (8-10). Many commercially available
CCMs lack such commutability for many analytes (10-14),
including lipase (3 ). The lack of commutability may not
be attributable to the declared characteristics of the CCMs,
but rather to the interaction between the characteristics of
the CCMs and the specificity of the analytical methods.
Accordingly, during the process of setting up a new
method, evaluation of the frequency of noncommutability
of CCMs would be useful when the new method is
compared with either a reference method or any other
method.
The aims of this work were the following: (a) to assess
the commutability of several commercially available
CCMs in two commercial lipase methods that use differ-
ent substrates; (b) to assess the impact of commutable and
noncommutable CCMs on normalizing patient sera re-
sults with different methods; and (c) to evaluate some
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characteristics of reagents that affect assay specificity and
commutability.
Materials and Methods
We assayed 98 fresh patient serum samples (singleton),
covering a wide interval of concentration values, and 29
commercially available CCMs (duplicate analyses) from
Beckman Analytical, Bio-Rad Laboratories, Merck, Ortho-
Clinical Diagnostics, Roche Diagnostics, and Sentinel. All
the CCMs had a human matrix.
Lipase measurements were performed on a Hitachi 912
automatic analyzer (Roche Diagnostics) at 37 °C with two
commercial methods and with four additional experi-
mental methods. One commercial method, designated as
“DG” (Sentinel), used 1,2-diglyceride as substrate (3, 15,
16 ). The other commercial method, designated as “CH”
(Roche Diagnostics), and the four experimental methods
used 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6-methyl-
resorufin) ester as substrate (17 ). All four experimental
methods (experimental reagents from Sentinel) contained
colipase, but differed from one another in stabilizing
proteins and in the size of substrate micelles: two methods
contained protein (0.3 g/L) and micelles with either a
250-nm (P250) or 400-nm (P400 method) diameter, respec-
tively; the two methods without added protein used
micelles with either a 250-nm (NP250) or 400-nm (NP400)
diameter.
In all our experiments, the CH method was arbitrarily
kept as the comparison method. The intermethod differ-
ences observed in the assay of CCMs were compared
graphically with those of patient sera (18 ). The inter-
method relationship in the assay of patient sera was also
assessed by means of the Passing and Bablok (19 ) non-
parametric linear regression; the dispersion around such a
line is estimated as residual SD (Syx). The nonparametric
correlation coefficient (Spearman r) was also calculated.
For each CCM, the residual was computed and then
divided by the residual SD of patient sera to yield the
normalized residual. The normalized residual of each
CCM was taken as the measure of its degree of commut-
ability (20, 21); normalized residuals outside the  3
interval were considered to indicate lack of commutabil-
ity.
To assess the effect of CCM noncommutability on
recalibration, the results for the entire set of patient sera
by the y-axis method (i. e., DG) were recalculated, taking
CCMs as calibrators, with values assigned by the x-axis
method (i. e., CH). Both single-point and two-point math-
ematical recalibrations were used because intermethod
comparison with patient sera revealed constant and pro-
portional components of intermethod differences. The
differences [(original y-axis value)  (x-axis value)] and
[(recalculated y-axis value)  (x-axis value)] were then
computed, and the distributions of such differences were
compared to assess the effect of recalibration (12-14).
Results
The intermethod differences (DG  CH) observed in the
assay of patient sera and CCMs are plotted against mean
enzyme activity in Fig. 1; the aberrant intermethod behav-
iors of some noncommutable CCMs are clearly shown.
Table 1 reports the statistical assessment (nonparametric
linear regression and correlation) of method-comparison
results. The normalized residuals of the 29 CCMs are
listed in Table 2; the noncommutability rate was 3/29
(10%), 18/29 (63%), 15/29 (52%), 5/29 (17%), and 13/29
(45%) when the DG, P250, P400, NP250, and NP400
methods, respectively, were compared with the CH
method. CCMs 1, 2, 3, 4, 5, 6, 7, 8, 14, and 18 were always
commutable, whereas CCM 11 was noncommutable in all
cases. CCMs 24 and 25 were noncommutable when the
four experimental methods (P250, P400, NP250, and
NP400, respectively) were compared with the CH
method. In our experiments, the overall noncommutabil-
ity rate was 19/70 (27%) for liquid CCMs and 35/75 (47%)
Fig. 1. Distribution of intermethod differences (DG  CH) vs concen-
tration. E, patient sera; Œ, commutable CCMs; f, noncommutable
CCMs.
Table 1. Statistical assessment (nonparametric linear
regression and correlation) of method-comparison results in
the assay of patient sera.a
Statistical
parameters
Compared method
DG P250 P400 NP250 NP400
n 98 98 98 98 98
Intercept, U/L 15.3 14.8 4.0 26.4 14.7
Slope 1.14 0.36 0.50 0.34 0.36
Residual SD, U/L 16.7 2.4 3.7 3.0 3.4
Correlation
coefficient,
Spearman r
0.943 0.977 0.984 0.967 0.970
a Results from each compared method (dependent variable) are compared
with those from the CH method (independent variable).
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for lyophilized CCMs. The degree of noncommutability of
each CCM, measured by the value of its normalized
residual, was somewhat related to its lipase activity when
the P250, P400, and NP400 methods were compared with
the CH method (Fig. 2).
To show the effect of recalibration with commutable
and noncommutable CCMs, the results generated by the
DG method for patient sera were recalculated, using
either commutable or noncommutable CCMs as calibra-
tors: CCMs 28 and 11 (normalized residuals, 0.5 and 6.0,
respectively) were chosen for single-point calibration; the
pairs of CCMs 3/28 and 27/29 (normalized residuals,
0.2/0.5 and 3.4/3.5, respectively) were chosen for
two-point calibration. Table 3 and Fig. 3 show the changes
in intermethod differences (method DG vs method CH)
after recalibration with commutable and noncommutable
CCMs. When two commutable CCMs were used, the
distribution of the intermethod differences improved: the
median intermethod difference tended to approach 0, the
slope of the nonparametric regression line tended to
approach 1, and the intercept value decreased. When one
commutable CCM was used, only the slope of the regres-
sion line improved because the single-point calibration
could not correct the constant component of intermethod
differences. When noncommutable CCMs were used in-
stead, the distributions of the differences deteriorated: the
median tended to move away from 0, the slope of the
regression line tended to move away from 1 (single-point
calibration), and the intercept of the regression line in-
creased (two-point calibration).
When a noncommutable CCM was used for recalibra-
tion, 5 pathologic results changed to nonpathologic val-
Table 2. Main characteristics and normalized residuals of the commercially available CCMs included in this study.
No. Product name
Physical
state
Lipase,a
U/L
Normalized residual
DG P250 P400 NP250 NP400
1 Synchron level 3b Liquid 26 0.7 0.9 0.5 0.3 0.3
2 Multiqual assayed 1c Liquid 34 0.4 1.0 0.4 2.3 0.3
3 Multiqual unassayed 1c Liquid 36 0.2 1.5 0.3 2.2 1.1
4 Ortho liquid control 1d Liquid 47 0.8 0.9 1.6 1.9 1.4
5 Multiqual unassayed 2c Liquid 56 0.1 1.1 0.9 0.6 0.2
6 Lyphochek unassayed 1c Lyophilized 61 0.0 2.4 1.8 0.2 0.8
7 Lyphochek assayed 1c Lyophilized 64 0.5 1.0 0.5 0.6 0.1
8 Liquichek unassayed 1c Liquid 67 0.6 1.2 0.7 0.3 0.2
9 Roche control serum Ne Lyophilized 76 0.3 3.5f 2.4 0.6 2.6
10 Synchron level 2b Liquid 79 0.4 3.8f 1.4 0.5 2.2
11 Multiqual assayed 3c Liquid 82 6.0f 21.7f 18.2f 13.4f 11.1f
12 Roche control serum Pe Lyophilized 84 0.0 3.5f 2.8 0.2 2.7
13 Calibrator lot F0915g Lyophilized 85 1.1 4.6f 3.0 0.2 3.5f
14 Ortho liquid control IId Liquid 87 0.1 2.3 2.6 1.5 2.4
15 Precinorm Ue Lyophilized 92 0.4 4.0f 3.1f 0.9 4.0f
16 Normal control serumg Lyophilized 96 1.1 4.9f 3.4f 0.0 5.1f
17 Lyphochek unassayed 2c Lyophilized 96 0.4 8.6f 6.8f 2.1 7.0f
18 Multiqual assayed 2c Liquid 98 0.8 0.6 0.5 2.3 0.5
19 Lyphochek assayed 2c Lyophilized 110 0.6 6.7f 4.9f 0.0 5.5f
20 Qualitrol HS Nh Lyophilized 117 0.7 8.7f 6.3f 2.0 6.9f
21 Liquichek unassayed 2c Liquid 118 0.6 8.1f 5.9f 0.8 6.6f
22 Synchron level 1b Liquid 126 0.4 9.4f 4.9f 0.0 7.2f
23 Clinical chemistry calibratorg Lyophilized 133 0.1 9.9f 7.2f 3.0 9.9f
24 Qualitrol HS Ph Lyophilized 137 0.5 12.0f 7.5f 4.0f 9.9f
25 c.f.a.s. calibratore Lyophilized 146 0.4 12.2f 7.8f 3.8f 9.4f
26 Precipath Ue Lyophilized 151 0.2 10.3f 6.5f 1.9 8.8f
27 Multiqual unassayed 3c Liquid 185 3.4f 10.9f 7.6f 3.7f 1.9
28 Calibrator lot H0622g Lyophilized 234 0.5 0.3 3.8f 3.2f 1.7
29 Ortho liquid control IIId Liquid 237 3.5f 7.1f 3.9f 0.1 2.6
a CH method.
b Beckman Analytical.
c Bio-Rad Laboratories.
d Ortho-Clinical Diagnostics.
e Roche Diagnostics.
f Noncommutable CCM.
g Sentinel.
h Merck.
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ues; when two noncommutable CCMs were used for
recalibration, 67 nonpathologic results turned to patho-
logic.
Discussion
When dealing with an enzyme acting at a lipid–water
interface, different assay methods, with different config-
urations of the substrate and in the presence of different
matrices, can be expected to give different results. None-
theless, one approach to standardizing enzyme activity
assays is to calibrate routine methods with CCMs that
have values assigned by a “comparison” method (22 ). For
such a procedure to be effective, the CCMs must be
commutable (23 ). Consistent with its definition (9 ), com-
mutability of CCMs with patient sera, in a stated pair of
methods, is considered here as a “relative” property,
comparing the intermethod behavior of each CCM with
the population of patient sera, whichever dispersion the
latter may show. The “standardized residual” is taken as
the measure of the intermethod behavior of a single
material (either patient serum or CCM), and to stay on the
safe side, the interval from 3 to 3 is taken as the
“reference interval” of the standardized residuals of pa-
tient sera. A CCM showing a standardized residual out-
side the  3 interval has 1% probability for its inter-
method behavior to belong to the patient sera population
and is, therefore, classified as noncommutable. As already
discussed (11 ), the wider the distribution of patient sera
standardized residuals, the higher the probability for a
CCM to be commutable with the patient sera in the
specific pair of methods.
The examples given here show that the recalibration
with commutable CCMs may permit a correction of the
original intermethod differences (Table 3), as already
shown for other components (13, 14, 23, 24). Two-point
recalibration more effectively corrected the constant com-
ponent of intermethod differences. The perverse effect of
recalibrating with noncommutable CCMs and the conse-
quent misinterpretation of patient results were also
shown. Many CCMs assayed for lipase in our experiments
were noncommutable in this work.
If noncommutable CCMs similar to those included in
the present study are used in external quality-assessment
schemes, the interlaboratory (intermethod) variability
measured may not be representative of the variability
observed in the assay of patient sera (25 ).
The reasons for the lack of commutability of the CCMs
are not always evident, but they are often ascribed to the
Fig. 2. Normalized residuals vs lipase activity concentration of the
commercial CCMs included in this study.
Comparison method (abscissa), CH. Compared methods (ordinate): E, DG; ‚,
P250; , P400; F, NP250; Œ, NP400.
Table 3. Statistical analysis of the intermethod differences (DG method vs CH method) before and after recalibration with
commutable and noncommutable CCMs.
Statistical parameter
Recalibration
None
Commutable CCMs Non-commutable CCMs
Single-point Two-point Single-point Two-point
Intermethod differences
Lowest value, U/L 28.0 52.0 51.1 194.3 7.2
2.5 centile, U/L 25.0 30.5 29.9 176.2 29.0
25 centile, U/L 14.0 17.4 11.3 62.3 43.4
Median, U/L 9.0 12.4 5.2 29.5 48.4
75 centile, U/L 4.8 5.3 0.4 21.8 55.4
97.5 centile, U/L 76.2 35.9 33.0 10.5 93.9
Highest value, U/L 84.0 45.3 43.9 4.9 104.0
Linear regression/correlation
Intercept, U/L 15.3 13.8 4.8 6.5 47.7
Slope 1.14 1.03 0.99 0.52 1.01
Residual SD, U/L 16.7 14.9 14.3 7.9 15.1
Correlation coefficient,
Spearman r
0.943 0.942 0.942 0.946 0.952
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matrix (25-27). Reportedly, all the CCMs assayed in our
experiments had a human matrix, but it was not declared
in their labels whether human, animal, or plant enzyme
had been added. Our data (Table 2) show that noncom-
mutability seems to be a more frequent event for lyophi-
lized CCMs: the overall noncommutability rate was 27%
for liquid CCMs and 47% for lyophilized CCMs. Also,
analyte concentration and degree of noncommutability
appeared related (Fig. 2). The degree of noncommutabil-
ity may be either related or not related to the analyte
concentration: whereas the latter pattern may be caused
mainly by matrix effects, it has been argued that differ-
ences in the analyte characteristics between patient sam-
ples and CCMs are mainly responsible for the former, as
may be the case with enzymes (24 ).
Because the occurrence of noncommutability may be
attributable to the interaction of the characteristics of the
CCMs with the specificity of the analytical methods, we
evaluated the frequency of noncommutability by analyz-
ing our set of patient sera and CCMs with four experi-
mental methods and with an established method. From a
general point of view, in clinical enzymology, one should
pay attention not to change the clinical reliability of an
established assay by changing the measuring method.
However, if new or modified assay methods are sug-
gested, these should be tested for their compatibility with
fresh human sera and with CCMs. Our data show that, for
the lipase assays that use 1,2-o-dilauryl-rac-glycero-3-
glutaric acid-(6-methylresorufin) ester as substrate, the
frequency of noncommutability may be affected by some
characteristics of the analytical method, such as size of
substrate micelles and the presence of stabilizing proteins
different from colipase. It seems interesting to note that
with substrate micelles of 250 nm, the simple addition of
the stabilizing proteins caused the frequency of noncom-
mutability to shift from 5/29 to 18/29.
We conclude that, as the lack of commutability seems
to be an unpredictable event attributable to the interaction
of the characteristics of the CCMs with the properties of
the analytical methods, it is necessary to check the com-
mutability of CCMs if they are to be used for assessing the
performance of different methods by external quality-
assessment schemes or to normalize patient results by
different methods. To minimize the frequency of noncom-
mutability, efforts should be made to improve both the
quality of the CCMs and the robustness of the methods,
thus allowing harmonization of results produced by dif-
ferent methods. The production of analytical results that
are true and comparable worldwide represents an impor-
tant contribution to the practice of evidence-based medi-
cine (28 ).
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